EligibleTrials

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting · NCT07229313 · Interventional (participants receive a specific treatment) · Lead sponsor: Kivu Bioscience Inc.

View the official record on ClinicalTrials.gov →
Breast cancerLung cancerColorectal cancerPancreatic cancer

Interventions studied

KIVU-107

What this trial is about

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

24 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.